Assistant Professor, Early Drug Development

Overview

Work type: University Medical Line
Location: Stanford University
Categories: School of Medicine

The Stanford Cancer Institute (SCI) at the Stanford University School of Medicine seeks a board-certified medical oncologist to join the Department of Medicine and the Division of Oncology as Assistant Professor in the University Medical Line. We are particularly interested in candidates with a focus on early-phase clinical trials.

• The major criteria for appointment for faculty in the University Medical Line shall be excellence in the overall mix of clinical care, clinical teaching, scholarly activity that advances clinical medicine, and institutional service appropriate to the programmatic need the individual is expected to fulfill.

Individuals appointed as Assistant Professors will have completed their house staff training and, where appropriate, postdoctoral fellowship training. They must demonstrate excellence or promise of excellence in the overall mix of contributions in clinical care, teaching and scholarly activity that advances clinical medicine appropriate to the programmatic need upon which the appointment will be based. There should be evidence that candidates have the promise to attain regional recognition for excellence in the overall mix of contributions.

If these individuals have not had formal teaching experience, they should have demonstrated during their house staff and fellowship training a commitment to teaching, and they should have the potential to meet or exceed acceptable standards in teaching.

The SCI leads an Early Drug Development (EDD) Program focused on Phase I clinical trials in oncology. These are typically studies where first in-human novel cancer therapeutics clinical trials are developed for our patients, incorporating biomarkers in their clinical design. Increasingly, these Phase I studies serve an important role in the oncology drug development ecosystem where not only toxicity, but efficacy data are acquired with the goal of improving the standard of care for oncology patients.

The successful candidate should be a fellowship-trained specialist in medical oncology, with a focus on early-phase clinical trials. Additionally, she or he should have a demonstrated track record or significant potential in obtaining research funding, along with a history of publishing in leading scientific or medical journals.

This position is open to candidates trained in developing and conducting early phase innovative clinical/translational trials with targeted agents and immunotherapeutics. The successful candidate will be expected to develop a clinical/translational research program, teach graduate students, postdoctoral fellows and clinical fellows, and participate in the Oncology clinics. The SCI and the Division of Oncology benefits from an outstanding scientific and clinical environment, including active collaboration with the basic science departments and other Stanford Institutes.

Eligible candidates must have an MD or MD/PhD and be board-certified in medical oncology.

The successful candidate will have experience working with a broad spectrum of investigators and, preferably, a dedicated interest in a particular disease area and/or focus on a therapeutic pathway, or experience with genomics and other biomarkers. Participation in relevant clinical and basic science conferences is also expected.

The mission of the Stanford Cancer Institute (SCI) is to leverage the broad and unique strengths of Stanford University in the sciences, in clinical care, and in translation to improve the diagnosis, treatment, and outcomes of cancer patients; to understand cancer etiologies among diverse populations; and to decrease cancer incidence. The SCI offers unique opportunities for the successful candidate to be integral to its mission and to join a faculty highly engaged in improving cancer research and patient care.

Stanford is an equal employment opportunity and affirmative action employer. All qualified applicants will receive consideration…